Skip to main content

Market Overview

UPDATE: Leerink Says Tekmira Is 'Uniquely Positioned'

Share:

Tekmira Pharmaceuticals (NASDAQ: TKMR) shares are trading seven percent higher Monday after Leerink revealed a $25 price target and Outperform rating.

The company has significant opportunity beyond Ebola with its RNAi product and pipeline, according to the research report. These factors make Tekmira “uniquely positioned.”

TKM-HBV, Tekmira’s hepatitis B drug has the potential to be a major growth catalyst says analyst Michael Schmidt. An investigational new drug application is expected to be filed in the second half of 2015.

Related Link: Deutsche Bank Raises Achillion Price Target 138%

Tekmira shares are up 106 percent over the past month; the company is one of few names mentioned in the recent Ebola outbreak. Shares fell 50 percent from peak to trough last week, but today’s rally is fueling a recovery.

The issue was last trading hands at $19.30, a 6.75 percent gain.

Latest Ratings for TKMR

DateFirmActionFromTo
Jun 2015Maxim GroupDowngradesBuyHold
Jun 2015Maxim GroupDowngradesHold
Nov 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for TKMR
View the Latest Analyst Ratings

 

Related Articles (TKMR)

View Comments and Join the Discussion!

Posted-In: Ebola Leerink Michael SchmidtAnalyst Color Price Target Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
LBCredit SuisseMaintains36.0
TRGPCredit SuisseMaintains40.0
SNOWCredit SuisseMaintains275.0
DARCredit SuisseMaintains95.0
CLRMKM PartnersDowngrades26.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com